LONDON – Results from two non-randomized phase I/II trials of the Russian COVID-19 vaccine Sputnik V that recently received conditional regulatory approval show both a frozen and a freeze-dried formulation of the two-shot vaccine had a good safety profile and induced antibody responses in all 76 participants within 21 days. Read More
The biopharma industry has raised a total of about $88 billion so far in 2020, the most ever for a single year, with four months to go. It hit the record in July when it surpassed the $68.4 billion raised in 2015. Read More
A nearly $2 billion global development and commercialization deal with Abbvie Inc. and a $418 million private placement have bolstered I-Mab Biopharma Co. Ltd.’s position globally. I-Mab framed the deal as being the largest out-licensing and global partnership transaction ever executed by a China-based biotech. Read More
Lixte Biotechnology Holdings Inc., a small OTC-listed company developing inhibitors of protein phosphatases to be used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers for treating cancer, has filed to raise $10.7 million in a public offering of shares on Nasdaq. Read More
With the PDUFA date for relugolix against prostate cancer growing nearer and data in castration resistance-free patients closer still, Myovant Sciences GmbH aims to wring more from the oral, once-daily gonadotropin-releasing hormone receptor antagonist, studying it in uterine fibroids and endometriosis. Read More
BioWorld looks at translational medicine, including: MTOR-targeting metabolite discovered; AKG for A-OK aging; Benzodiazepine and barbiturate binding to GABA-A; Giving misfolded proteins a second chance; Agrin-culture grows cartilage; SCAD vs. plaques in heart attacks. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alligator, Amag, Ampio, Biontech, Blade, Crinetics, Hutchison China Meditech, Lexicon, Mesoblast, Oncopeptides, Relay, Savara. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Arcturus, Bioaegis, Curevac, Nanoviricides, Organovo. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ascendis, Kite, Lilly. Read More
